Bankrupt microbiome-testing startup uBiome, once valued at $600 million by Silicon Valley investors, preliminarily sold its patents at auction to a DNA-testing outfit called Psomagen for less than 1% of the company’s original value on Monday, a person with direct knowledge of the matter told STAT.

Psomagen is a genetic sequencing company that sells personal DNA tests including a gut health test, according to its website. A subsidiary of South Korean biotech Macrogen, the company has at least 25 U.S. employees, all based in Maryland, according to LinkedIn. On Monday, Psomagen offered $7 million for uBiome’s patents portfolio and related intellectual property, according to the source and public bankruptcy documents. No other bidders came forward with a competing offer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy